Barclays initiated coverage of BeOne Medicines (ONC) with an Overweight rating and $385 price target The company’s “broad” oncology pipeline ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

The bispecific antibodies in oncology market is anticipated to experience substantial growth in the coming years. This growth ...